NEW YORK – HalioDx on Tuesday announced an extended strategic collaboration with Kite Pharma aimed at developing and validating immune-based biomarkers for the drug firm's investigational therapies.
The deal covers multiple blood cancer and solid tumor indications and will leverage Marseille, France-based HalioDx's Immunoscore immune-based tests. Immunogram, the company's multiparameter approach for the analysis of the immune microenvironment of tumors, as well as HalioDx's Cancer Immune Atlas will also be used.
Corinne Danan, executive vice president of the pharma business unit at HalioDx, said in a statement that her firm and Kite, a Santa Monica, California-based subsidiary of Gilead Sciences, have worked together since 2016. "Our first studies have highlighted the relevance of HalioDx's multimodal Immunogram approach," she said. "Our extended collaboration will enable us to further validate these data but also to expand the benefits of this approach beyond blood cancers."
Financial and other terms of the deal were not disclosed.